Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
cSCC is one of the most common cancers in the U.S. and globally
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines
Subscribe To Our Newsletter & Stay Updated